Breaking News

4 Nov 2026

Reading the Brain’s Response: Enveric’s EB-003 Takes a Step Toward Human Testing

By Madison Roberts

Industry

3 Nov 2026

The Cost of Waiting: What Compass’s Depression Survey Means for Psychedelic Medicine

By Madison Roberts

Breaking News

21 Oct 2026

Beyond the Psychedelic Experience: Enveric Biosciences Takes Another Step Toward a New Generation of Mental Health Treatments

By Madison Roberts

Industry

27 Aug 2026

Ibogaine’s Momentum Is Real. So Is the Safety Gap Nobody’s Solving.

Recent reporting, has documented a string of serious adverse events at overseas psychedelic clinics such as cardiac deaths, treatment-related fatalities, and patients who were never adequately screened for the health...

By Madison Roberts

ADVERTISEMENT

Explore the Marketplace

Dive into a world where wellness meets innovation, and discover a curated selection of products designed to elevate your everyday life. Our marketplace offers a wide range of high-quality functional mushroom products, delicious gummies, and unique merchandise and clothing.

Industry News

27 Aug 2026

Ibogaine’s Momentum Is Real. So Is the Safety Gap Nobody’s Solving.

Recent reporting, has documented a string of serious adverse events at overseas psychedelic clinics such as cardiac deaths, treatment-related fatalities, and patients who were never adequately screened for the health...

By Madison Roberts

11 Aug 2026

Psychedelic Medicine Is Having an Identity Crisis — And That’s a Good Thing

For most of the last decade, the story of psychedelic medicine was a story about the trip itself. Guided sessions. Eyeshades and headphones. A therapist sitting with a patient for...

By Madison Roberts

11 Aug 2026

Enveric Biosciences Adds Another Data Point to Its Case That EB-003 Won’t Get You High

Enveric Biosciences is trying to answer one of the trickiest questions in the psychedelic drug space: can you get the antidepressant benefits people associate with psychedelics without the trip? On...

By Madison Roberts

28 Jul 2026

FDA’s New Psychedelic Guidance Signals a Maturing Industry. Now Comes the Hard Part.

For years, the psychedelic medicine industry has operated in largely uncharted regulatory territory. Companies developing psilocybin, LSD, MDMA, and next-generation psychedelic-inspired compounds have often found themselves navigating a clinical landscape...

By Madison Roberts

13 Jul 2026

The Psychedelic Sector Has Grown Up. Wall Street Just Hasn’t Fully Realized It Yet

The sector experienced an early wave of enthusiasm fueled by bold promises, lofty valuations, and the belief that psychedelic medicine would quickly transform mental healthcare. Reality, however, proved more complicated....

By Madison Roberts

9 Feb 2026

Two New Studies Are Rewriting the Rules of Psychedelic Drug Development

For much of the last decade, psychedelic medicine has been driven by clinical outcomes first and mechanistic explanations second. Promising results in depression, anxiety, and trauma propelled compounds like psilocybin...

By Madison Roberts

Online Courses

New Liposomal Mushroom Sleep Aid

Fall Asleep Rapidly

Where strong competitor products may take 30 minutes before sleep pressure begins, our Deeper Sleep Tablets take less than 1 minute.

“I tried this last night and within 5-10 mins out cold and when I woke up I felt completely rested and refreshed”

– Tim S (Verified Customer)

Culture

19 Nov 2025

Childhood Trauma’s Role in Men’s Substance Use Disorders

Childhood trauma leaves a deeper imprint on men’s lives than most realize—and for many, it becomes the hidden engine driving substance use disorders. Research shows that emotional abuse, physical violence,...

By Madison Roberts

19 Nov 2025

Human-Centered AI in Healthcare

Artificial intelligence is redefining modern healthcare, offering powerful tools that enhance diagnosis, expedite drug discovery, and enable truly personalized treatment. As health systems struggle with rising costs, aging populations, and...

By Madison Roberts

10 Oct 2025

After the Billion-Dollar Psychedelic Bet: Who’s Next for Big Pharma?

In the wake of Gilgamesh’s billion-dollar exit, a new wave of companies is emerging, smaller, stealthier, and far more scientifically disciplined than their first-wave predecessors. Their mission: harness the therapeutic...

By Madison Roberts

12 Sep 2025

Bridging Psychedelics, Psychiatry, and Spirituality for Global Healing

As psychedelic medicine continues its rapid reentry into mainstream science, few voices have managed to bridge the worlds of psychiatry, spirituality, and policy as seamlessly as Dr. Anna Yusim. With...

By Madison Roberts

9 Sep 2025

Global Psychedelic Week Announces In-Person Events

The inaugural Global Psychedelic Week, taking place November 3–9, 2025, brings together thought leaders, activists, and enthusiasts from over 100 countries. Featuring a hybrid model of online sessions and in-person...

By Madison Roberts

5 Feb 2025

Microdosing & Women’s Hormones: A Revolutionary Approach to Healing

For too long, women’s health has been reduced to symptom management—birth control, hormone patches, and endless supplements. But what if true healing isn’t about masking symptoms, but restoring balance at...

By Madison Roberts

Latest Arrivals

Join Our Newsletter for Exclusive Updates, Stories, and More

The World on Drugs

Watch our internationally award-winning documentary, plus over 11 hours of additional interviews featuring Dr. Gabor Mate, Paul Stamets, Dennis McKenna, and more.

Finance

25 Feb 2025

Enveric Biosciences’ Patent For Non-Hallucinogenic Psychedelic Compounds

Enveric Biosciences (NASDAQ: ENVB) has received its first U.S. patent for the EVM401 Series, a collection of non-hallucinogenic compounds derived from mescaline. These novel therapeutics target multiple neurological receptors associated...

By Madison Roberts

8 May 2024

A Pioneering Push in Cancer Treatment: Enveric Biosciences Advances with Cannabinoid Therapies

Enveric Biosciences, a notable player in biotechnological innovations, has recently announced a significant licensing agreement that might change the landscape of cancer treatment....

By Madison Roberts

29 Apr 2024

Unlocking New Horizons: Enveric Biosciences’ Strategic Moves in Biotechnology

Enveric Biosciences has signed two non-binding term sheets to out-license novel cannabinoid-COX-2 conjugate compounds for joint disease treatment, with potential financial gains from milestone payments and royalties totaling up to...

By Madison Roberts

cybin deal

11 Dec 2023

Tryp Therapeutics To Be Acquired by Exopharm

Tryp Therapeutics announces signing of definitive agreement with Exopharm Limited....

By Microdose NewsDesk

24 Nov 2023

Filament Health Announces US$14.4 million Funding & Planned NASDAQ Listing

Filament Health has signed a non-binding term sheet for up to US$14.4 million in funding through a convertible note....

By Microdose NewsDesk

18 Oct 2023

Spravato Sales Lead J&J Third Quarter Results

Johnson & Johnson has released its 3rd quarter results and once again Spravato sales have shown impressive growth....

By Jason Najum

ADVERTISEMENT

Science

28 Aug 2025

AbbVie’s $1B Psychedelic Bet: Who’s Next in the Neuroplastogen Gold Rush?

AbbVie’s quiet acquisition of Gilgamesh Pharmaceuticals, reportedly worth close to $1 billion, did more than make headlines. It signaled something far more significant: Big Pharma has officially entered the psychedelic-adjacent...

By Madison Roberts

18 Aug 2025

Enveric Biosciences: Poised to Outshine Traditional Psychedelic Targets

But while traditional psychedelic developers dominate headlines, Enveric Biosciences (NASDAQ: ENVB) has stayed quietly in the background, focusing on an equally groundbreaking, but less flashy, approach: non-hallucinogenic neuroplastogens, small molecules...

By Madison Roberts

23 Jul 2025

Enveric’s Latest Patent Signals a Clear Path Forward for PTSD Drug Development

This week, Enveric announced it has received a second U.S. patent allowance for compounds in its EVM401 Series, expanding its growing intellectual property fortress. These aren’t just any molecules —...

By Madison Roberts

15 Jul 2025

Enveric’s EB-003 Shows Promise in PTSD Model, Offering a New Direction in Trauma Treatment

Enveric Biosciences announced that its lead compound, EB-003, significantly reduced trauma-related fear behaviors in a preclinical PTSD model—highlighting its potential as a fast-acting, non-hallucinogenic treatment for a condition with few...

By Madison Roberts

1 Jul 2025

Enveric’s EB-003 Shows Dual Mechanism Promise, Paving a New Path in Neuropsychiatric Drug Innovation

Enveric Biosciences (NASDAQ: ENVB) is quietly making a case to lead the next generation of neuropsychiatric drug innovation. On June 24, the company announced new data that could significantly broaden...

By Madison Roberts

3 Jun 2025

Enveric’s Patent Win Targets New Frontiers in Sleep Medicine

With U.S. Patent No. 12,187,679 now granted, Enveric Biosciences has secured more than intellectual property—it’s staked a claim on the future of neurotherapeutics. The Cambridge-based biotech firm announced this week...

By Madison Roberts

Professional Training in Psychedelic Medicine

Psychedelic medicine is reshaping the future of mental health care. From the power of microdosing LSD to the promise of MDMA in PTSD, the world of medical psychedelics offers transformative possibilities. Our comprehensive, CE-accredited course provides you with the knowledge and understanding you need to tap into this groundbreaking field.

ADVERTISEMENT

Health & Wellness

12 Sep 2025

Bridging Psychedelics, Psychiatry, and Spirituality for Global Healing

As psychedelic medicine continues its rapid reentry into mainstream science, few voices have managed to bridge the worlds of psychiatry, spirituality, and policy as seamlessly as Dr. Anna Yusim. With...

By Madison Roberts

18 Aug 2025

Enveric Biosciences: Poised to Outshine Traditional Psychedelic Targets

But while traditional psychedelic developers dominate headlines, Enveric Biosciences (NASDAQ: ENVB) has stayed quietly in the background, focusing on an equally groundbreaking, but less flashy, approach: non-hallucinogenic neuroplastogens, small molecules...

By Madison Roberts

15 Jul 2025

Enveric’s EB-003 Shows Promise in PTSD Model, Offering a New Direction in Trauma Treatment

Enveric Biosciences announced that its lead compound, EB-003, significantly reduced trauma-related fear behaviors in a preclinical PTSD model—highlighting its potential as a fast-acting, non-hallucinogenic treatment for a condition with few...

By Madison Roberts

19 May 2025

Healing Beyond Addiction: New Research Shows Family Relationships Key to Lasting Recovery

Family healing plays a critical role in overcoming addiction, increasing recovery success rates by up to 50%. Despite this, a severe shortage of mental health professionals leaves many Texans without...

By Madison Roberts

28 Apr 2025

The New Epidemic: How Trauma and Digital Exposure Are Shaping a Teen Mental Health Crisis

The mental health of today's teens is under unprecedented strain, with trauma and digital saturation driving record levels of anxiety, depression, and suicidal ideation. In “Impact of Trauma and Digital...

By Madison Roberts

5 Feb 2025

Microdosing & Women’s Hormones: A Revolutionary Approach to Healing

For too long, women’s health has been reduced to symptom management—birth control, hormone patches, and endless supplements. But what if true healing isn’t about masking symptoms, but restoring balance at...

By Madison Roberts

Our mission is to shift the world's perception of psychedelic medicine

Feature your products in the Marketplace

Speak with us about selling your products in our online marketplace.

Learn More

Schedule an interview

We want to tell your story. Speak with our team to get you in front of the spotlight.

Learn More

Advertise with us

We offer advertising options that reach across all our platforms, letting you define how you want to connect.

Learn More

Another cool idea? We're all ears

Simply put, we love cool sh*t. If you have an idea or potential collaboration, don’t hesitate to reach out.

Learn More

Breaking News

21 Apr 2026

Trump’s Psychedelic Fast-Track Order Changes the Timeline. It Also Redraws the Competitive Map.

President Donald Trump’s April 2026 executive order on accelerating treatments for serious mental illness does something the psychedelic industry has been waiting for, and quietly fearing. It removes ambiguity. For...

By Madison Roberts

Breaking News

25 Feb 2026

AbbVie Withdraws Patent Challenge, Clearing Path for Enveric’s Psychedelic IP Strategy

In a development that could ripple across the fast evolving neuroplastogen sector, Enveric Biosciences announced that a Post Grant Review petition filed against one of its key U.S. patents has...

By Madison Roberts

Breaking News

19 Feb 2026

Breaking: Enveric Reports New Mechanistic Data Supporting Non-Hallucinogenic Neuroplastogen Strategy

By Madison Roberts

Breaking News, Industry

9 Feb 2026

Two New Studies Are Rewriting the Rules of Psychedelic Drug Development

For much of the last decade, psychedelic medicine has been driven by clinical outcomes first and mechanistic explanations second. Promising results in depression, anxiety, and trauma propelled compounds like psilocybin...

By Madison Roberts

Industry

19 Jan 2026

Starting 2026: Why Neuroplastogens Are Quietly Redefining the Psychedelic Medicine Narrative

An industry wide look at how neuroplastogens are reshaping psychedelic medicine in 2026, with insights on Delix, AbbVie’s Gilgamesh acquisition, Enveric, and the shift toward nonhallucinogenic brain therapeutics....

By Madison Roberts

Industry

17 Dec 2025

Psychedelics in 2025: A Year of Proof, Pullback, and a Clearer Path Forward

If 2024 was the year the psychedelic field learned how hard “approval ready” really is, 2025 was the year it began behaving accordingly. The past twelve months were less about...

By Madison Roberts

Breaking News

26 Nov 2025

Delix Therapeutics Reports Strong Phase Ib Results

Delix Therapeutics recently announced compelling data from a Phase Ib trial of DLX-001 (zalsupindole), a non-hallucinogenic neuroplastogen. According to the company’s release, DLX-001 produced robust biomarker signals (quantitative EEG and...

By Madison Roberts

Culture

19 Nov 2025

Childhood Trauma’s Role in Men’s Substance Use Disorders

Childhood trauma leaves a deeper imprint on men’s lives than most realize—and for many, it becomes the hidden engine driving substance use disorders. Research shows that emotional abuse, physical violence,...

By Madison Roberts

Culture, Industry

19 Nov 2025

Human-Centered AI in Healthcare

Artificial intelligence is redefining modern healthcare, offering powerful tools that enhance diagnosis, expedite drug discovery, and enable truly personalized treatment. As health systems struggle with rising costs, aging populations, and...

By Madison Roberts

Breaking News

16 Oct 2025

Enveric Biosciences Doubles Down on IP Strength as Psychedelic Biotech Sector Heats Up

As Big Pharma makes billion-dollar bets in the evolving landscape of neuropsychiatric therapeutics, Enveric Biosciences (NASDAQ: ENVB) is carving out a formidable position — not by chasing headlines, but by...

By Madison Roberts

Breaking News

15 Oct 2025

The IP Battle Behind the $1.2B Psychedelic Acquisition—and Why Enveric Biosciences Is a Name to Watch

Take Enveric Biosciences (NASDAQ: ENVB), a company that’s been flying under the radar while building an IP fortress around a novel class of non-hallucinogenic neuroplastogens. Now, that fortress is being...

By Madison Roberts

Culture, Industry, Psychedelic Groundbreakers

10 Oct 2025

After the Billion-Dollar Psychedelic Bet: Who’s Next for Big Pharma?

In the wake of Gilgamesh’s billion-dollar exit, a new wave of companies is emerging, smaller, stealthier, and far more scientifically disciplined than their first-wave predecessors. Their mission: harness the therapeutic...

By Madison Roberts

Law & Politics

23 Sep 2025

Psylutions and the DEA

In August 2025, the psychedelics movement crossed an unprecedented threshold. The U.S. Drug Enforcement Administration (DEA) announced that it would forward a petition to reschedule psilocybin, the psychoactive compound found...

By Madison Roberts

Breaking News

16 Sep 2025

With big pharma circling psychedelics, the next breakthrough may not come from tripping at all

When AbbVie moved to acquire Gilgamesh Pharmaceuticals in a deal valued at more than $1 billion, it sent shockwaves through the biotech community. For years, psychedelic-inspired drug development has been...

By Madison Roberts

Culture, Health & Wellness

12 Sep 2025

Bridging Psychedelics, Psychiatry, and Spirituality for Global Healing

As psychedelic medicine continues its rapid reentry into mainstream science, few voices have managed to bridge the worlds of psychiatry, spirituality, and policy as seamlessly as Dr. Anna Yusim. With...

By Madison Roberts

Breaking News, Culture

9 Sep 2025

Global Psychedelic Week Announces In-Person Events

The inaugural Global Psychedelic Week, taking place November 3–9, 2025, brings together thought leaders, activists, and enthusiasts from over 100 countries. Featuring a hybrid model of online sessions and in-person...

By Madison Roberts

Breaking News, Press Releases, Psychedelic Groundbreakers, Psychedelic Titans, Science

28 Aug 2025

AbbVie’s $1B Psychedelic Bet: Who’s Next in the Neuroplastogen Gold Rush?

AbbVie’s quiet acquisition of Gilgamesh Pharmaceuticals, reportedly worth close to $1 billion, did more than make headlines. It signaled something far more significant: Big Pharma has officially entered the psychedelic-adjacent...

By Madison Roberts

Breaking News, Health & Wellness, Industry, Psychedelic Groundbreakers, Psychedelic Titans, Science

18 Aug 2025

Enveric Biosciences: Poised to Outshine Traditional Psychedelic Targets

But while traditional psychedelic developers dominate headlines, Enveric Biosciences (NASDAQ: ENVB) has stayed quietly in the background, focusing on an equally groundbreaking, but less flashy, approach: non-hallucinogenic neuroplastogens, small molecules...

By Madison Roberts

Breaking News, Industry, Press Releases, Psychedelic Groundbreakers, Science

23 Jul 2025

Enveric’s Latest Patent Signals a Clear Path Forward for PTSD Drug Development

This week, Enveric announced it has received a second U.S. patent allowance for compounds in its EVM401 Series, expanding its growing intellectual property fortress. These aren’t just any molecules —...

By Madison Roberts

Breaking News, Health & Wellness, Industry, Press Releases, Psychedelic Groundbreakers, Psychedelic Titans, Science

15 Jul 2025

Enveric’s EB-003 Shows Promise in PTSD Model, Offering a New Direction in Trauma Treatment

Enveric Biosciences announced that its lead compound, EB-003, significantly reduced trauma-related fear behaviors in a preclinical PTSD model—highlighting its potential as a fast-acting, non-hallucinogenic treatment for a condition with few...

By Madison Roberts

Breaking News, Industry, Science

1 Jul 2025

Enveric’s EB-003 Shows Dual Mechanism Promise, Paving a New Path in Neuropsychiatric Drug Innovation

Enveric Biosciences (NASDAQ: ENVB) is quietly making a case to lead the next generation of neuropsychiatric drug innovation. On June 24, the company announced new data that could significantly broaden...

By Madison Roberts

Breaking News, Press Releases, Science

3 Jun 2025

Enveric’s Patent Win Targets New Frontiers in Sleep Medicine

With U.S. Patent No. 12,187,679 now granted, Enveric Biosciences has secured more than intellectual property—it’s staked a claim on the future of neurotherapeutics. The Cambridge-based biotech firm announced this week...

By Madison Roberts

Industry

20 May 2025

Enveric Biosciences Stakes Its Claim in Neurodegeneration Market

Enveric Biosciences is quietly making a bold move into the neurodegenerative disease space with a new class of molecules targeting the critical BDNF/TrKB pathway. While still in early stages, this...

By Madison Roberts

Health & Wellness

19 May 2025

Healing Beyond Addiction: New Research Shows Family Relationships Key to Lasting Recovery

Family healing plays a critical role in overcoming addiction, increasing recovery success rates by up to 50%. Despite this, a severe shortage of mental health professionals leaves many Texans without...

By Madison Roberts

Science

8 May 2025

A Psychedelic Turning Point: How a Landmark Review Re‑frames Psilocybin’s Role in Treating Addiction

Groundbreaking analysis of every modern clinical study on psilocybin for substance‑use disorders shows the psychedelic, when delivered with structured therapy, can dramatically cut drinking and smoking rates and sustain long‑term...

By Madison Roberts

Healing, Health & Wellness

28 Apr 2025

The New Epidemic: How Trauma and Digital Exposure Are Shaping a Teen Mental Health Crisis

The mental health of today's teens is under unprecedented strain, with trauma and digital saturation driving record levels of anxiety, depression, and suicidal ideation. In “Impact of Trauma and Digital...

By Madison Roberts

Industry

8 Apr 2025

No More Silence: The Opioid Epidemics Alarming Impact on Women

Women are facing a silent crisis in the opioid epidemic, with overdose deaths among women aged 30–64 skyrocketing by 260% since 1999. Beyond the statistics lie the stories of mothers,...

By Madison Roberts

Industry, Psychedelic Titans, Science

31 Mar 2025

The Future of Psychedelics: Why Next-Generation Molecules Will Win

The psychedelic industry is undergoing a major transformation. With new, non-hallucinogenic compounds on the rise, companies like Enveric Biosciences, Delix Therapeutics, and Gilgamesh Pharmaceuticals are leading the way in developing...

By Madison Roberts

Breaking News, Finance, Press Releases

25 Feb 2025

Enveric Biosciences’ Patent For Non-Hallucinogenic Psychedelic Compounds

Enveric Biosciences (NASDAQ: ENVB) has received its first U.S. patent for the EVM401 Series, a collection of non-hallucinogenic compounds derived from mescaline. These novel therapeutics target multiple neurological receptors associated...

By Madison Roberts

Culture, Healing, Health & Wellness

5 Feb 2025

Microdosing & Women’s Hormones: A Revolutionary Approach to Healing

For too long, women’s health has been reduced to symptom management—birth control, hormone patches, and endless supplements. But what if true healing isn’t about masking symptoms, but restoring balance at...

By Madison Roberts

WordPress Ads